Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 5/20 | 0.62 |
| ▸ | CTSL | P07711 | 9/20 | 0.59 |
| ▸ | CTSK | P43235 | 9/20 | 0.59 |
| ▸ | CTSS | P25774 | 7/20 | 0.57 |
| ▸ | CTSB | P07858 | 2/20 | 0.57 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.52 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.52 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.52 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.52 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.52 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8526673 | 1.00 | REN (0.62) | RENCTSLCTSKCTSSCTSB | |
| SCHEMBL8528279 | 0.92 | PSEN1 (0.57) | RENCTSLCTSKPSEN1PSEN2 | |
| SCHEMBL3498556 | 0.91 | CTSS (0.64) | RENCTSLCTSKCTSSCTSB | |
| SCHEMBL7295862 | 0.91 | CTSS (0.69) | RENCTSLCTSKCTSSCTSB | |
| SCHEMBL5050550 | 0.91 | CTSS (0.69) | RENCTSLCTSKCTSSCTSB | |
| SCHEMBL7295855 | 0.91 | CTSS (0.69) | RENCTSLCTSKCTSSCTSB | |
| SCHEMBL11599759 | 0.89 | CTSS (0.55) | RENCTSLCTSKCTSSCTSB | |
| SCHEMBL2402235 | 0.86 | CTSS (0.60) | CTSLCTSKCTSSCTSB | |
| SCHEMBL3922795 | 0.86 | CTSS (0.60) | CTSLCTSKCTSSCTSB | |
| SCHEMBL6292769 | 0.86 | CTSS (0.60) | CTSLCTSKCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368424-B2 | Acylated nonadepsipeptides | AICURIS GMBH & CO. KG (DE) | 2008-05-06 | — | — | US | disclosed |
| US-20050075281-A1 | peptide antibiotics comprising lysobactin derivatives used for treatment and/or prophylaxis of bacterial infectious diseases; cyclic peptides | BAYER HEALTHCARE AG (DE) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075281-A1 | peptide antibiotics comprising lysobactin derivatives used for treatment and/or prophylaxis of bacterial infectious diseases; cyclic peptides | VIP, LNPEP, HAMP | REN 1354/4885CTSL 65/4885CTSK 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.